Simultaneous Estimation of Lamivudine and Dolutegravir in Tablet Dosage Form by RP-HPLC: Development and Validation
International Journal of Drug Delivery Technology · 05.05.2026 · 16 (24s)
DOI: 10.25258/ijddt.16.24s.82 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 05.05.2026. Verfasst von Keerthisikha Palur und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Reliable and validated analytical methods are indispensable for ensuring the quality and safety of pharmaceutical products. The present work aimed to develop and validate a sensitive, accurate, precise, and economical reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of Lamivudine and Dolutegravir in tablet dosage form. Chromatographic separation was achieved on an Agilent C18 column (150 mm × 4.6 mm, 5 µm) using a mobile phase of orthophosphoric acid and acetonitrile (60:40 v/v) at a flow rate of 1 mL/min with UV detection at 260 nm. Column temperature was maintained at 30°C with an injection volume of 10 µL. Retention times were 2.250 min for Lamivudine and 2.875 min for Dolutegravir. The method was validated for linearity, precision, accuracy, robustness, limit of detection (LOD), and limit of quantification (LOQ) as per ICH Q2(R1) guidelines. Excellent linearity was observed over the concentration ranges studied, with regression equations y = 3455x + 10272 (Lamivudine) and y = 30992x + 5402 (Dolutegravir). Precision studies yielded %RSD values of 0.6% and 0.3% for Lamivudine and Dolutegravir, respectively. Mean percentage recovery values were 99.95% and 99.62%, confirming method accuracy. LOD and LOQ were 0.27 and 0.81 µg/mL for Lamivudine and 0.11 and 0.34 µg/mL for Dolutegravir. The developed RP-HPLC method was found to be simple, rapid, accurate, and suitable for routine quality control analysis of Lamivudine and Dolutegravir in tablet dosage forms.
Zitieren
APA
Palur, K., Archakam, S. C., Sujitha, Y. S., Chaitanya, P., & Jyothika, M. (2026). Simultaneous Estimation of Lamivudine and Dolutegravir in Tablet Dosage Form by RP-HPLC: Development and Validation. International Journal of Drug Delivery Technology, 16(24s). https://doi.org/10.25258/ijddt.16.24s.82
Vancouver
Palur K, Archakam SC, Sujitha YS, Chaitanya P, Jyothika M. Simultaneous Estimation of Lamivudine and Dolutegravir in Tablet Dosage Form by RP-HPLC: Development and Validation. International Journal of Drug Delivery Technology. 2026;16(24s). doi:10.25258/ijddt.16.24s.82
BibTeX
@article{Palur2026,
author = {Palur, Keerthisikha and Archakam, Sreenivasa Charan and Sujitha, Y Sarah and Chaitanya, P and Jyothika, M},
title = {Simultaneous Estimation of Lamivudine and Dolutegravir in Tablet Dosage Form by RP-HPLC: Development and Validation},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {24s},
doi = {10.25258/ijddt.16.24s.82}
}
EUVIMED